Real-World Experience Favors a Neoadjuvant Strategy of Chemoimmunotherapy for Locoregionally Advanced NSCLC
-
Published:2024-09
Issue:3
Volume:118
Page:681-682
-
ISSN:0003-4975
-
Container-title:The Annals of Thoracic Surgery
-
language:en
-
Short-container-title:The Annals of Thoracic Surgery
Reference6 articles.
1. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet,2021
2. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022
3. Perioperative durvalumab for resectable non-small-cell lung cancer;Heymach;N Engl J Med,2023
4. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O'Brien;Lancet Oncol,2022
5. Perioperative pembrolizumab for early-stage non-small-cell lung cancer;Wakelee;N Engl J Med,2023